Table 1 The baseline data of all patients with SCLC stratified by OS and CSS status
OS | CSS | P | |||||
|---|---|---|---|---|---|---|---|
Alive (N = 2803) | Dead (N = 4016) | P | Alive (N = 3179) | Dead (N = 3640) | |||
Age | < 50 years | 80(2.854) | 80(1.992) | < 0.001 | 85(2.674) | 75(2.060) | 0.018 |
50–59 years | 470(16.768) | 625(15.563) | 523(16.452) | 572(15.714) | |||
60–69 years | 1122(40.029) | 1500(37.351) | 1252(39.383) | 1370(37.637) | |||
70–79 years | 915(32.644) | 1392(34.661) | 1055(33.187) | 1252(34.396) | |||
> 80 years | 216(7.706) | 419(10.433) | 264(8.304) | 371(10.192) | |||
Gender | male | 1237(44.131) | 2037(50.722) | < 0.001 | 1424(44.794) | 1850(50.824) | < 0.001 |
female | 1566(55.869) | 1979(49.278) | 1755(55.206) | 1790(49.176) | |||
Household income | < $60,000 | 878(31.324) | 1380(34.363) | 0.009 | 1014(31.897) | 1244(34.176) | 0.046 |
≥ $60,000 | 1925(68.676) | 2636(65.637) | 2165(68.103) | 2396(65.824) | |||
Race | American Indian | 23(0.821) | 42(1.046) | 0.017 | 25(0.786) | 40(1.099) | 0.023 |
Asian | 124(4.424) | 125(3.113) | 133(4.184) | 116(3.187) | |||
Black | 258(9.204) | 342(8.516) | 299(9.405) | 301(8.269) | |||
White | 2398(85.551) | 3507(87.326) | 2722(85.624) | 3183(87.445) | |||
Treatment delay | no | 1134(40.457) | 1872(46.614) | < 0.001 | 1290(40.579) | 1716(47.143) | < 0.001 |
yes | 1669(59.543) | 2144(53.386) | 1889(59.421) | 1924(52.857) | |||
Radiation | no | 862(30.753) | 1767(43.999) | < 0.001 | 1014(31.897) | 1615(44.368) | < 0.001 |
yes | 1941(69.247) | 2249(56.001) | 2165(68.103) | 2025(55.632) | |||
Primary site | upper lobe | 1826(65.144) | 2555(63.621) | 0.642 | 2068(65.052) | 2313(63.544) | 0.364 |
middle lobe | 141(5.030) | 211(5.254) | 152(4.781) | 200(5.495) | |||
lower lobe | 776(27.685) | 1159(28.860) | 894(28.122) | 1041(28.599) | |||
overlapping lesion | 60(2.141) | 91(2.266) | 65(2.045) | 86(2.363) | |||
Laterality | left | 2790(99.750) | 4002(99.800) | 0.660 | 3166(99.779) | 3626(99.780) | 0.997 |
right | 7(0.250) | 8(0.200) | 7(0.221) | 8(0.220) | |||
T stage | T1 | 896(31.966) | 796(19.821) | < 0.001 | 1000(31.456) | 692(19.011) | < 0.001 |
T2 | 576(20.549) | 850(21.165) | 654(20.573) | 772(21.209) | |||
T3 | 473(16.875) | 781(19.447) | 554(17.427) | 700(19.231) | |||
T4 | 858(30.610) | 1589(39.567) | 971(30.544) | 1476(40.549) | |||
N stage | N0 | 678(24.188) | 570(14.193) | < 0.001 | 757(23.813) | 491(13.489) | < 0.001 |
N1 | 342(12.201) | 354(8.815) | 384(12.079) | 312(8.571) | |||
N2 | 1198(42.740) | 2015(50.174) | 1376(43.284) | 1837(50.467) | |||
N3 | 585(20.870) | 1077(26.818) | 662(20.824) | 1000(27.473) | |||
M stage | M0 | 1682(60.007) | 1255(31.250) | < 0.001 | 1870(58.824) | 1067(29.313) | < 0.001 |
M1 | 1121(39.993) | 2761(68.750) | 1309(41.176) | 2573(70.687) | |||
Clinical stage | early | 652(23.261) | 300(7.470) | < 0.001 | 718(22.586) | 234(6.429) | < 0.001 |
advanced | 2151(76.739) | 3716(92.530) | 2461(77.414) | 3406(93.571) | |||
Scope of regional lymph nodes | none | 1601(85.798) | 2668(96.737) | < 0.001 | 1851(86.901) | 2418(96.953) | < 0.001 |
1–3 removed | 45(2.412) | 25(0.906) | 49(2.300) | 21(0.842) | |||
≥ 4 removed | 220(11.790) | 65(2.357) | 230(10.798) | 55(2.205) | |||
Chemotherapy | no | 196(6.993) | 549(13.670) | < 0.001 | 242(7.612) | 503(13.819) | < 0.001 |
yes | 2607(93.007) | 3467(86.330) | 2937(92.388) | 3137(86.181) | |||
Tumor metastasis | no | 1712(61.077) | 1303(32.445) | < 0.001 | 1904(59.893) | 1111(30.522) | < 0.001 |
yes | 1091(38.923) | 2713(67.555) | 1275(40.107) | 2529(69.478) | |||